文献速递肿瘤 PET/CT核素与放射性配体治疗

具有优化骨架的治疗诊断PSMA配体用于前列腺癌术中多模态成像与光动力治疗

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-14

本研究通过对现有PSMA配体骨架(PSMA-1007/PSMA-617)进行关键修饰,开发了三种基于光敏剂的双标记PSMA配体,用于多模态成像和靶向前列腺癌光动力治疗。在细胞和小鼠模型中,新骨架结构产生了高亲和力PSMA配体(所有IC50<50 nM),配体介导的光动力治疗在体外导致PSMA特异性细胞活力下降(P<0.001)。连接子修饰显著改善了肿瘤靶向性,与先前开发的PSMA-N064配体相比(≥20±3%ID/g vs 14±2%ID/g,P<0.01),并在小鼠中实现了PSMA阳性肿瘤的放射性核素和荧光成像特异性可视化。

要点

  • 新骨架结构产生高亲和力PSMA配体,所有IC50<50 nM。
  • 配体介导的光动力治疗在体外导致PSMA特异性细胞活力下降(P<0.001)。
  • 连接子修饰显著改善肿瘤靶向性:≥20±3%ID/g vs 14±2%ID/g(P<0.01)。

核心结论

  • 具有优化骨架组成的新型高亲和力双标记PSMA靶向配体显示出增加的肿瘤靶向性,并实现了多模态图像引导的前列腺癌手术联合靶向光动力治疗。

研究设计与样本

  • 研究合成了多种新型PSMA配体,使用固相化学并提供DOTA螯合剂用于111In标记以及荧光团/光敏剂IRDye700DX。
  • 将三种新型双标记配体的性能与先前发表的第一代配体(PSMA-N064)和具有不完整PSMA结合基序的对照配体进行比较。
  • 在LS174T-PSMA细胞和对照LS174T野生型细胞中测定PSMA特异性、亲和力和光动力治疗效力。
  • 在携带皮下LS174T-PSMA和LS174T野生型肿瘤的BALB/c裸鼠中,使用µSPECT/CT成像、荧光成像和解剖后生物分布研究评估肿瘤靶向特性。

主要发现

  • 为合成新型双标记配体,通过将谷氨酸替换为赖氨酸残基修饰PSMA肽连接子,为多个功能部分的偶联提供手柄。
  • 配体优化显示新骨架结构导致高亲和力PSMA配体(所有IC50<50 nM)。
  • 配体介导的光动力治疗在体外导致PSMA特异性细胞活力下降(P<0.001)。
  • 连接子修饰与先前开发的PSMA-N064配体相比显著改善肿瘤靶向性(≥20±3%ID/g vs 14±2%ID/g,P<0.01)。
  • 在小鼠中,使用放射性核素和荧光成像均实现了PSMA阳性肿瘤的特异性可视化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The first generation ligands for prostate-specific membrane antigen (PSMA)-targeted radio- and fluorescence-guided surgery followed by adjuvant photodynamic therapy (PDT) have already shown the potential of this approach. Here, we developed three new photosensitizer-based dual-labeled PSMA ligands by crucial modification of existing PSMA ligand backbone structures (PSMA-1007/PSMA-617) for multimodal imaging and targeted PDT of PCa. METHODS: Various new PSMA ligands were synthesized using solid-phase chemistry and provided with a DOTA chelator for 111In labeling and the fluorophore/photosensitizer IRDye700DX. The performance of three new dual-labeled ligands was compared with a previously published first-generation ligand (PSMA-N064) and a control ligand with an incomplete PSMA-binding motif. PSMA specificity, affinity, and PDT efficacy of these ligands were determined in LS174T-PSMA cells and control LS174T wildtype cells. Tumor targeting properties were evaluated in BALB/c nude mice with subcutaneous LS174T-PSMA and LS174T wildtype tumors using µSPECT/CT imaging, fluorescence imaging, and biodistribution studies after dissection. RESULTS: In order to synthesize the new dual-labeled ligands, we modified the PSMA peptide linker by substitution of a glutamic acid into a lysine residue, providing a handle for conjugation of multiple functional moieties. Ligand optimization showed that the new backbone structure leads to high-affinity PSMA ligands (all IC50 < 50 nM). Moreover, ligand-mediated PDT led to a PSMA-specific decrease in cell viability in vitro (P < 0.001). Linker modification significantly improved tumor targeting compared to the previously developed PSMA-N064 ligand (≥ 20 ± 3%ID/g vs 14 ± 2%ID/g, P < 0.01) and enabled specific visualization of PMSA-positive tumors using both radionuclide and fluorescence imaging in mice. CONCLUSION: The new high-affinity dual-labeled PSMA-targeting ligands with optimized backbone compositions showed increased tumor targeting and enabled multimodal image-guided PCa surgery combined with targeted photodynamic therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Derks YHW, van Lith SAM, Amatdjais-Groenen HIV, et al. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35029739. doi:10.1007/s00259-022-05685-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。